Investigate Md

Scottsdale, Arizona 86260

1 studies enrolling now · 16 studies all time

What they study most

Alopecia, Alopecia Areata, Alopecia, Androgenetic, Areata Alopecia, Atopic Dermatitis, Body Fat Disorder, Glabellar Lines, Hair Diseases, Hypotrichosis, Keloid, Muscle Weakness, Nasolabial Folds

Studies at this site

• A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata — Recruiting now
• Safety and Effectiveness of ELLANSÉ®-S Dermal Filler in the Treatment of Nasolabial Folds — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) — Running, not enrolling
• A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata — Completed
• A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2) — Completed
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer — Running, not enrolling
• Magnetic Muscle Stimulation of Abdominal Muscle — Stopped early
• Effects on Cellulite Appearance — Completed
• Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata — Completed
• A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence — Completed
• A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC — Completed
• CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts — Completed
• MT10109L in the Treatment of Glabellar Lines — Completed
• Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis — Completed
• Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. — Completed